Information Provided By: 
Fly News Breaks for March 16, 2017
INO
Mar 16, 2017 | 07:55 EDT
Maxim analyst Jason McCarthy upgraded Inovio to Buy from Hold and set a $10 price target on the stock, stating that it has multiple earlier stage programs moving forward with more significant data points coming in 2017 while it moves closer to its pivotal study in cervical dysplasia. He notes that his model assumes that VGX-3100 is commercialized in 2021 for cervical dysplasia.
News For INO From the Last 2 Days
There are no results for your query INO
